340031 RESULTS
RESEARCH MODELS Summary These mice are deficient in PSEN1. This model is perinatal lethal in homozygouse animals which die shortly after birth, presumably from breathing difficulties due to ribcage deformity (Shen et al., 1997). Gross skeletal malformations and central n
RESEARCH MODELS Modification Details Transgene containing human APP (isoform 695) with the London mutation driven by the Thy1 promoter. Neuropathology Plaques start in the subiculum at ten months, spreading to the frontal cortex as dense and diffuse aggregates. Frequent
RESEARCH MODELS Neuropathology Tau hyperphosphorylation and conformational changes in the brain parenchyma start around seven months. Tangle-like pathology is mainly observed in the brain stem and spinal cord, and to a lesser extent in the midbrain and cerebral cortex (T
RESEARCH MODELS Summary These are bigenic mice that overexpress both mutant APP (V717I mutation) and mutant PSEN1 (A246E mutation). They were first generated and described by the laboratory of Fred Van Leuven (Dewachter et al., 2000). The transgenes are coexpressed in th
RESEARCH MODELS Summary The Senescence Accelerated Mouse-Prone 8 (SAMP8) is a naturally occuring mouse line that displays a phenotype of accelerated aging. While maintaining an inbred AKR/J line in the early 1970's, researchers at Kyoto University became aware that
ALZPEDIA Progranulin burst on the scene of neurodegenerative disease as a major genetic cause of frontotemporal dementia (FTD) in 2006, only months before TDP-43 was identified as the main protein constituent of the histopathological lesions in the same patients.
PROTOCOL This assay was designed to detect small amounts of tau seeds in biological samples, such as brain homogenates from humans or rodent tauopathy models. HEK-293T cells stably expressing a human tau sequence were engineered to serve as biosensors of intracell
RESEARCH MODELS Summary These transgenic mice express a chimeric mouse/human APP carrying the Swedish mutation under the control of the mouse prion protein promoter. This line, C3-3, was generated in parallel with line E1-2, which also expresses APP carrying the Swedish
RESEARCH MODELS Summary The first report of this transgenic line described two lines of mice that overexpress human PSEN1 with the M146L mutation, line 5.1 and line 6.2 (Duff et al., 1996). Line 5.1 has been more extensively characterized, especially in relation to the d
ALZPEDIA The sortilin-related receptor SORLA is an endocytic receptor that belongs to the vacuolar protein sorting 10 (VPS10) domain receptor family. SORLA binds to the amyloid precursor protein (APP). It functions as an intracellular sorting receptor as APP is be
COMMENT This necessary study supports, once again, the idea that microglia do not affect plaque formation in mouse models unless they are "activated" by drugs or immunotherapy or replaced by fresh macrophages. Whether this applies to humans, too, remain
COMMENT A very interesting finding, indeed! saak.ovsepian 0
COMMENT This study is most interesting. It gives strong evidence that manipulation of the innate immune system is an important therapeutic target for AD. The authors have shown that stimulation of innate immunity via TLR9 leads to reduction in both Aβ and tau-rel
COMMENT This is a very interesting concept. Almost three decades ago, we postulated the same hypothesis, based on histologic analysis of aged brains, demonstrating a blood brain barrier (BBB) breakdown and leakage of serum proteins in aged (but not young) human b
COMMENT The study by Hill et al. is a beautiful illustration of how structure predicts function. As Dr. Attwell has pointed out, a primary controversy here is a difficulty in identifying cells that reside at the junction between arterioles and capillaries. We rec
